Citizens reiterates Market Outperform rating on Abivax stock at $114 target
PositiveFinancial Markets

Citizens has reaffirmed its Market Outperform rating on Abivax stock, setting a target price of $114. This endorsement is significant as it reflects confidence in Abivax's potential for growth and success in the market, which could attract more investors and boost the company's stock performance.
— Curated by the World Pulse Now AI Editorial System












